Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Gergana Zahmanova
 -- 2398 2023-12-19 11:16:15 |
2 update references and layout
Rita Xu
Meta information modification 2398 2023-12-20 02:32:04 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Zahmanova, G.; Aljabali, A.A.A.; Takova, K.; Minkov, G.; Tambuwala, M.M.; Minkov, I.; Lomonossoff, G.P. Green Biologics. Encyclopedia. Available online: https://encyclopedia.pub/entry/52920 (accessed on 20 May 2024).
Zahmanova G, Aljabali AAA, Takova K, Minkov G, Tambuwala MM, Minkov I, et al. Green Biologics. Encyclopedia. Available at: https://encyclopedia.pub/entry/52920. Accessed May 20, 2024.
Zahmanova, Gergana, Alaa A. A. Aljabali, Katerina Takova, George Minkov, Murtaza M. Tambuwala, Ivan Minkov, George P. Lomonossoff. "Green Biologics" Encyclopedia, https://encyclopedia.pub/entry/52920 (accessed May 20, 2024).
Zahmanova, G., Aljabali, A.A.A., Takova, K., Minkov, G., Tambuwala, M.M., Minkov, I., & Lomonossoff, G.P. (2023, December 19). Green Biologics. In Encyclopedia. https://encyclopedia.pub/entry/52920
Zahmanova, Gergana, et al. "Green Biologics." Encyclopedia. Web. 19 December, 2023.
Green Biologics
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms242417575

Plants are increasingly used for the production of high-quality biological molecules for use as pharmaceuticals and biomaterials in industry. Plants have proved that they can produce life-saving therapeutic proteins (Elelyso™—Gaucher’s disease treatment, ZMapp™—anti-Ebola monoclonal antibodies, seasonal flu vaccine, Covifenz™—SARS-CoV-2 virus-like particle vaccine); however, some of these therapeutic proteins are difficult to bring to market, which leads to serious difficulties for the manufacturing companies.

plant-derived biologics plant-based expression systems plant molecular farming

1. Introduction

Protein-based biologics are the fastest-growing class of pharmaceutical products, manufactured from engineered biological sources. Plants can be engineered to produce various types of biologics (antibodies, vaccines, enzymes, therapeutic proteins, hormones, and cytokines), as well as recombinant proteins for cosmetics, food, and the chemical industry, in addition to research and diagnostic purposes. The process is known as plant molecular farming (PMF) [1][2][3][4]. PMF offers a safe, cost-effective, and scalable production of unique multimeric proteins, ensuring fast and global-scale deployment of biologics and other valuable recombinant proteins [5]. These advantages make plants an efficient alternative to the traditional expression systems such as bacterial, yeast, insect, and mammalian cells, which cannot fully satisfy global needs for biologics and industrial proteins [6][7][8]. The successful implementation of well-established practices, such as plant cell engineering and optimization of biosynthetic pathways through cell medium improvement or genome editing, increased yields by using different methods of expression, or improving downstream processing (DSP), has led to optimization and maturation of PMF processes [9][10][11]. Companies producing plant-derived recombinant proteins for industrial purposes have seen sustainable success overall. In the pharmaceutical sector, however, this success has been limited to just a few notable examples (Elelyso™, ELFABRIOTM, and growth factors). This is most likely due to a lack of regulatory frameworks, an inability of plant-based expression systems to compete with established industrial platforms, and the reluctance of large pharmaceutical companies to reorganize their manufacturing processes [12][13].

2. Types of Plant-Derived Biologics

Plant-derived protein-based biologics represent a diverse array of molecules that can be produced using plants as an expression system [14][15][16]. They often have highly complex structures containing additional moieties (glycocarbohydrates and fatty acids) and can be divided into several major categories: monoclonal antibodies (mAbs), vaccines, enzymes for replacement therapies, receptor modulators, and bioactive small molecules [17].

2.1. Antibodies and Antibody Fragments

Plant-based expression systems have been leveraged for producing monoclonal antibodies and antibody fragments, known as “plantibodies.” Their applications include therapeutics, diagnostics, and research. Plantibodies have already successfully targeted infectious agents, cancer biomarkers, and therapeutic entities [18]. During the 2014 Ebola outbreak, for instance, the plant-based production of ZMapp (a cocktail of monoclonal antibodies) significantly increased the survival rate of infected patients [19], though the small number of patients treated makes a statistical evaluation of efficacy difficult. Plantibodies offer potential advantages in terms of reduced production costs, scalability, and customization.

2.2. Vaccines and VLPs

Plants present an appealing platform for vaccine production due to their ability to express immunogenic viral and bacterial antigens, as well as highly organized virus-like particles (VLPs) [20][21][22][23][24]. VLPs are self-assembling virus coat proteins resembling viruses but devoid of genetic material, which makes them safe for use in vaccines and nanoparticle production. Plant-derived VLPs and chimeric VLPs (composed of structural proteins or immunogenic epitopes from different viruses) are used as immune modulators and self-adjuvants in order to provoke strong immune responses against different viral diseases, as well as others such as cancer, allergies, and autoimmune diseases [5][25][26][27][28]. Plant-derived vaccines offer a multitude of benefits, including reduced production costs, improved stability, minimal cold chain requirements, and the possibility of oral delivery. Notably, edible vaccines have emerged, utilizing genetically engineered plants to express vaccine antigens. This innovative approach holds great promise for transforming vaccine delivery, particularly in developing countries where oral administration can eliminate the need for injections and cold chain storage. However, a major disadvantage is controlling the vaccination dose [8][21][29].
Furthermore, VLPs can be used as nanoparticles for drug delivery systems [30].

2.3. Therapeutic Enzymes

Plants efficiently produce various recombinant enzymes with clinically improved profiles. For example, ElelysoTM (β-glucocerebrosidase) has an improved profile compared to its CHO-made counterpart because the final plant-derived β-glucocerebrosidase contains terminal mannose residues, which are a key factor in the success of enzyme replacement therapy for Gaucher’s disease treatment [31][32]. Further, plant-made enzymes can be delivered orally, due to the cellulose wall of plant cells that makes them resistant to degradation [33]. Recombinant protein medications are shielded from stomach acids and digestive enzymes by the plant cell wall polymers, which have β 1,4 and β 1,6-glycosidic linkages that are resistant to hydrolysis [34]. Commensal microorganisms in the intestinal epithelium break down the plant cell wall, releasing the bioencapsulated recombinant proteins, which are recognized by the gut-associated lymphoid tissues (GALT) and induce an adaptive immune response [35][36]. Utilization of plant expression systems offers numerous advantages and has demonstrated promising outcomes in both preclinical and clinical studies, presenting a potential alternative to traditional biologic production methods [37][38][39]. Notably, plant-based expression systems have facilitated the cost-effective production of complex recombinant proteins, revolutionizing human and animal health management [5][40][41].

2.4. Receptor Modulators

Plant-based expression systems have been successfully used for the production of various small polypeptides and glycoproteins involved in the regulation processes in mammalian cells, such as cytokines and hormones [42][43]. Human growth hormone (hGH) produced in N. benthamiana plants demonstrated its biological activity in a hypophysectomized rat [43]. Cytokines are signaling proteins that help control inflammation in the body and can be used in the treatment of cancer, immune disorders, and various other related diseases. Erythropoietin [44], IL-2 [45], IL-4 [46], IL-12 [47], IL-13 [48], IL-18 [49], cardiotrophin 1 [50], human granulocyte-macrophage colony-stimulating factor (GM-CSF) [51][52][53][54], tumor necrosis factor-alpha (TNF) [55], interferon-alpha [56], human fibroblast growth factor 8b [57], and insulin-like growth factor 1 [58] have been expressed in different plant species using various methods for increasing recombinant protein yield and stability.

2.5. Small Molecules

Plants are a natural source of many medicinal compounds based on secondary metabolites, such as triterpenoids, alkaloids, and phenolics. These are synthesized through multi-step biosynthetic pathways involving a variety of different enzyme activities, and the active products have a highly specific stereochemistry. Such medicinal compounds can be extracted from the native species; however, in many cases, propagation of the plants and the low yields of extractable compounds and their subsequent purification make this an expensive procedure. The alternative of complete chemical synthesis is generally impractical due to the complex structures of the compounds. For these reasons, attention has turned to the detailed characterization of the biosynthetic pathways for plant-derived metabolites with the aim of reconstructing them in more tractable organisms through the co-expression of the relevant biosynthetic enzymes. Such an approach also allows variants of naturally produced molecules to be produced through the combinatorial expression of different enzymes.
A dramatic early example of this approach was the reconstruction of the biosynthetic pathway for the anti-malarial compound artemisinin in yeast [59]. Subsequently, the relevant enzymes have been transferred to other organisms, including plants more tractable than Artemisia annua, especially N. benthamiana (reviewed by Zhao et al., 2022) [60]. Though stable transformation has been used in plants, the “go-to” method is transient expression of the relevant enzymes. Not only is this much quicker than stable transformation, but it also allows a combinatorial approach for making a wide variety of related compounds that have differing bioactivities [61][62]. This ability has been exploited to great effect in the case of triterpenes [63][64], culminating in the transient combinatorial expression of 16 enzymes in N. benthamiana to produce a saponin molecule suitable for further bioengineering to produce adjuvants for use with vaccines [65]. This approach has also been used in studies to elucidate the biosynthetic pathway of the anticancer drugs vinblastine [66][67] and paclitaxel [68]. Though, at the time of writing, none of the molecules produced in this way have made it to deployment in medicine, the technology has great promise.

2.6. Bioactive Proteins from Plants

Plant-derived biologics also encompass bioactive molecules, such as lectins. Lectins are natural proteins that can bind carbohydrates that are highly specific for the sugar groups of other molecules. Some of the lectins have potent antimicrobial activity through binding to carbohydrates on microbial surfaces and inducing changes in cell permeability and pore formation [69]. Their biological activities make them useful as microbicides, antitumor agents, and vaccine adjuvants [70][71][72]. Mistletoe lectins (ML-I, ML-II, and ML-III) were transiently expressed in N. benthamiana and demonstrated anticancer activity [73].

3. Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis of Biologics

One of the primary advantages of harnessing plant-derived biologics lies in their inherent safety profile and reduced unwanted immunogenicity, which paves the way for enhanced patient tolerance and minimized adverse effects [74]. The plant glycan moieties’ immunogenicity has been the subject of extensive studies, and various animal models have been investigated to elucidate the immunogenicity of plant-derived glycoproteins [75][76]. The (1,2) xylose and (1,3) fucose structures have been recognized as cross-reactive carbohydrate determinants as a result of the discovery of IgE antibodies in allergy patients that cross-react with these structures on glycoproteins from a variety of species [77]. Plant-derived taliglucerase alfa (TGA), Protalix, contains tri-mannose glycoform with the addition of β(1,2) xylose and α(1,3) fucose, which are present at above 90% of the total glycan pool. No overtly adverse effects that could be related to these N-glycan residues have been observed in a clinical trial with TG involving healthy human volunteers, and no anti-drug antibodies have been found [78].
Additionally, whole plants and plant cell suspension cultures, which are free from animal pathogens and toxins, are suitable for oral delivery of biologics without purification or with minimal purification [33][79]. Production of oral biopharmaceuticals in edible plant tissues has proven to be efficacious in several clinical vaccinations for disease prevention [80][81][82][83]. The ability of plant cell walls to protect the plant-made biologic from enzymatic degradation in the gastrointestinal tract and the ability of these biologics to reach the lymphoid tissue in the gut in their active form can lead to the induction of oral tolerance, the prevention of unwanted immune responses, and the prevention of allergic responses [84][85][86][87]. Furthermore, the cost-effective production and scalability of these biopharmaceuticals present an opportunity to address the escalating healthcare costs and global disparities in access to essential medications [88][89]. By capitalizing on the inherent adaptability of plants, scientists can usher in a new era of personalized medicine, where targeted therapies are tailored to individual patients, boosting treatment outcomes and improving overall patient well-being [90]. In light of these remarkable advancements, it becomes increasingly evident that plant-derived biologics represent a transformative force in the field of biopharmaceuticals, offering a multifaceted solution to the pressing challenges faced by modern medicine [91]. Noteworthy stories, such as the development of plant-based antibodies or VLPs for treating cancer and the utilization of plant-produced vaccines for infectious diseases, underscore the efficacy and potential of these biologics [92][93][94][95][96][97][98][99]. Moreover, the environmental sustainability of plant-derived biologics deserves recognition. Their production systems boast lower carbon footprints, reduced energy requirements, and decreased reliance on non-renewable resources compared to other biological production methods. Addressing regulatory and safety considerations is paramount. Adherence to guidelines established by regulatory agencies ensures the approval and quality control of these biologics; however, unwavering vigilance is still necessary to guarantee safety and efficacy throughout the production process. Further, they also have weaknesses in terms of time consumption, variable yields, regulatory considerations, and protein degradation. Threats include intellectual property barriers, competition, and public perception. Continued research, development, and regulatory efforts are crucial to overcome these challenges and fully realize the potential of plant-derived biologics [15][100].

4. Manufacturing of Plant-Based Production Systems

Many of the original technical weaknesses of PMF, such as low yields, low recovery of recombinant proteins after downstream processing, and the impact of specific glycosylation in plants, have been overcome in some cases. Introducing technologies, such as stable plastid transformation, plant cell cultures, transient expression, agrobacterium infiltration, modeling of the plant glycosylation pathway, plant genome editing for improving the biosynthetic pathways in plants, increasing protein stability, and the production in current Good Manufacturing Practice (cGMP), will lead to scaling up the manufacturing of functional, unique recombinant proteins in plants [7][101][102][103][104][105][106]. The main steps in the development of PDB are presented in Figure 1.
Figure 1. Main steps in the production of biologics in plants. Valuable recombinant proteins are produced in stable transgenic whole plants (nuclear or chloroplast) using stable transgenic plant cell cultures and transient expression via agroinfiltration or modified plant viruses.
The extraordinary variety of plant species with specific useful characteristics enables the development of a wide variety of plant production systems [12]. Tobacco, maize, rice, potato, tomato, carrot, and lettuce are commonly used plant species for stable (nucleus or chloroplast) transformation [105][107][108][109][110][111]. Plant cell culture systems such as ProCellEx® and tobacco cell cultures (BY-2 and NT-1) covered the criteria for a high yield, precise control of environments and cell growth conditions, production according to good manufacturing practices, and regulatory compliance [112]. These advantages of plant cell systems have brought them to market with two products (β-glucocerebrosidase and a vaccine against Newcastle disease virus) approved, respectively, by the US Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) [113][114]. Plant cell suspension cultures are a connecting link between plants and current commercial cell-based production platforms. Furthermore, higher plants are not the only ones used for the production of therapeutic protein cell suspension systems: Chlamydomonas reinhardtii (alga), Lemna minor (duckweed), and Physcomitrella patens (moss) [115]. In addition to expression within living cells, a cell-free system based on BY-2 cells harvested in the exponential growth phase has been investigated as a means of synthesizing proteins. Yields of up to 270 μg/mL have been obtained when producing the yellow fluorescent protein (eYFP) using this approach [116].
The tobacco relative, Nicotiana benthamiana, is the most frequently used plant in molecular farming to produce recombinant proteins using transient expression [117][118][119]. N. benthamiana is characterized by the accumulation of a large biomass in a short period, reduced gene silencing, and being the most suitable plant species for transient expression using plant virus-based vectors and agrobacterium infiltration [20][120][121][122][123]. Utilization of plant viruses, such as tobacco mosaic virus (TMV) or cowpea mosaic virus (CPMV), as full virus vectors for delivering foreign genes into plants began in the 1980s [124][125][126][127]. Later on, these first-generation (gene substitution or insertion vectors) were replaced by deconstructed vector systems [128][129][130]. The deconstructed vectors contain only the viral genome components essential for effective protein expression, allowing the production of up to 80% of total soluble protein (magnICON) [131]. Furthermore, multiple gene expression leads to the accumulation of multi-subunit proteins such as VLPs, IgA, and IgM [132]. Plants with engineered post-translational modifications (glycosylation mutants and expression of recombinant glycosylation enzymes) have been developed for the proper production of recombinant glycoproteins [133][134][135]. New techniques such as CRISPR/Cas9 genome editing have been used to engineer the endogenous N-glycosylation machinery of the plants to generate N. benthamiana with deficient α-1,3-fucosyltransferase and β-1,2-xylosyltransferase activity [136].

References

  1. Alvarez, M.A. Plants for Health: From Secondary Metabolites to Molecular Farming Chapter 1. In Plant Biotechnology for Health: From Secondary Metabolites to Molecular Farming; Alvarez, M.A., Ed.; Springer International Publishing: Cham, Switzerland, 2014; pp. 1–2. ISBN 978-3-319-05771-2.
  2. Rybicki, E.P.; Chikwamba, R.; Koch, M.; Rhodes, J.I.; Groenewald, J.-H. Plant-Made Therapeutics: An Emerging Platform in South Africa. Biotechnol. Adv. 2012, 30, 449–459.
  3. Sil, B.; Jha, S. Plants: The Future Pharmaceutical Factory. Am. J. Plant Sci. 2014, 5, 319–327.
  4. Buyel, J.F. Plant Molecular Farming—Integration and Exploitation of Side Streams to Achieve Sustainable Biomanufacturing. Front. Plant Sci. 2019, 9, 1893.
  5. Zahmanova, G.; Aljabali, A.A.; Takova, K.; Toneva, V.; Tambuwala, M.M.; Andonov, A.P.; Lukov, G.L.; Minkov, I. The Plant Viruses and Molecular Farming: How Beneficial They Might Be for Human and Animal Health? Int. J. Mol. Sci. 2023, 24, 1533.
  6. Shanmugaraj, B.; Bulaon, C.J.I.; Phoolcharoen, W. Plant Molecular Farming: A Viable Platform for Recombinant Biopharmaceutical Production. Plants 2020, 9, E842.
  7. Fischer, R.; Buyel, J.F. Molecular Farming—The Slope of Enlightenment. Biotechnol. Adv. 2020, 40, 107519.
  8. Chung, Y.H.; Church, D.; Koellhoffer, E.C.; Osota, E.; Shukla, S.; Rybicki, E.P.; Pokorski, J.K.; Steinmetz, N.F. Integrating Plant Molecular Farming and Materials Research for Next-Generation Vaccines. Nat. Rev. Mater 2022, 7, 372–388.
  9. Buyel, J.F.; Twyman, R.M.; Fischer, R. Extraction and Downstream Processing of Plant-Derived Recombinant Proteins. Biotechnol. Adv. 2015, 33, 902–913.
  10. Buyel, J.F.; Stöger, E.; Bortesi, L. Targeted Genome Editing of Plants and Plant Cells for Biomanufacturing. Transgenic Res. 2021, 30, 401–426.
  11. Wiltschi, B.; Cernava, T.; Dennig, A.; Galindo Casas, M.; Geier, M.; Gruber, S.; Haberbauer, M.; Heidinger, P.; Herrero Acero, E.; Kratzer, R.; et al. Enzymes Revolutionize the Bioproduction of Value-Added Compounds: From Enzyme Discovery to Special Applications. Biotechnol. Adv. 2020, 40, 107520.
  12. Schillberg, S.; Finnern, R. Plant Molecular Farming for the Production of Valuable Proteins—Critical Evaluation of Achievements and Future Challenges. J. Plant Physiol. 2021, 258–259, 153359.
  13. Nandi, S.; Kwong, A.T.; Holtz, B.R.; Erwin, R.L.; Marcel, S.; McDonald, K.A. Techno-Economic Analysis of a Transient Plant-Based Platform for Monoclonal Antibody Production. MABS 2016, 8, 1456–1466.
  14. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural Products in Drug Discovery: Advances and Opportunities. Nat. Rev. Drug Discov. 2021, 20, 200–216.
  15. Chen, Q.; Santi, L.; Zhang, C. Plant-Made Biologics. Biomed Res. Int. 2014, 2014, 418064.
  16. Chen, Q.; Lai, H. Plant-Derived Virus-like Particles as Vaccines. Hum. Vaccines Immunother. 2013, 9, 26–49.
  17. Chan, J.C.N.; Chan, A.T.C. Biologics and Biosimilars: What, Why and How? ESMO Open 2017, 2, e000180.
  18. Liu, C.; Morrow, K.J., Jr. Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development; John Wiley & Sons: New York, NY, USA, 2016; ISBN 1-118-66231-8.
  19. Oldstone, M.B.A.; Rose Oldstone, M. Chapter 5—ZMapp: The Ethics of Decision Making. In Ebola’s Curse; Oldstone, M.B.A., Rose Oldstone, M., Eds.; Academic Press: Cambridge, MA, USA, 2017; pp. 49–62. ISBN 978-0-12-813888-5.
  20. Thuenemann, E.C.; Lenzi, P.; Love, A.J.; Taliansky, M.; Bécares, M.; Zuñiga, S.; Enjuanes, L.; Zahmanova, G.G.; Minkov, I.N.; Matić, S.; et al. The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants. Curr. Pharm. Des. 2013, 19, 5564–5573.
  21. Zahmanova, G.; Takova, K.; Valkova, R.; Toneva, V.; Minkov, I.; Andonov, A.; Lukov, G.L. Plant-Derived Recombinant Vaccines against Zoonotic Viruses. Life 2022, 12, 156.
  22. Zahmanova, G.; Naimov, S.; Mazalovska, M.; Valkova, R.; Minkov, I. Transient Expression of Modified Hepatitis B Capsid Protein in Nicotiana Benthamiana Plants for Viral Nanoparticles Production. J. BioScience Biotechnol. 2014, 2014, 11–16.
  23. Ponndorf, D.; Meshcheriakova, Y.; Thuenemann, E.C.; Dobon Alonso, A.; Overman, R.; Holton, N.; Dowall, S.; Kennedy, E.; Stocks, M.; Lomonossoff, G.P.; et al. Plant-Made Dengue Virus-like Particles Produced by Co-Expression of Structural and Non-Structural Proteins Induce a Humoral Immune Response in Mice. Plant Biotechnol. J. 2021, 19, 745–756.
  24. Peyret, H.; Steele, J.F.C.; Jung, J.-W.; Thuenemann, E.C.; Meshcheriakova, Y.; Lomonossoff, G.P. Producing Vaccines against Enveloped Viruses in Plants: Making the Impossible, Difficult. Vaccines 2021, 9, 780.
  25. Balke, I.; Zeltins, A. Recent Advances in the Use of Plant Virus-Like Particles as Vaccines. Viruses 2020, 12, 270.
  26. Wang, C.; Beiss, V.; Steinmetz, N.F. Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties. J. Virol. 2019, 93, e00129-19.
  27. Mardanova, E.S.; Takova, K.H.; Toneva, V.T.; Zahmanova, G.G.; Tsybalova, L.M.; Ravin, N.V. A Plant-Based Transient Expression System for the Rapid Production of Highly Immunogenic Hepatitis E Virus-like Particles. Biotechnol. Lett. 2020, 42, 2441–2446.
  28. Marsian, J.; Lomonossoff, G.P. Molecular Pharming—VLPs Made in Plants. Curr. Opin. Biotechnol. 2016, 37, 201–206.
  29. Nikitin, N.; Vasiliev, Y.; Kovalenko, A.; Ryabchevskaya, E.; Kondakova, O.; Evtushenko, E.; Karpova, O. Plant Viruses as Adjuvants for Next-Generation Vaccines and Immunotherapy. Vaccines 2023, 11, 1372.
  30. Chung, Y.H.; Cai, H.; Steinmetz, N.F. Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications. Adv. Drug Deliv. Rev. 2020, 156, 214–235.
  31. Shaaltiel, Y.; Bartfeld, D.; Hashmueli, S.; Baum, G.; Brill-Almon, E.; Galili, G.; Dym, O.; Boldin-Adamsky, S.A.; Silman, I.; Sussman, J.L.; et al. Production of Glucocerebrosidase with Terminal Mannose Glycans for Enzyme Replacement Therapy of Gaucher’s Disease Using a Plant Cell System. Plant Biotechnol. J. 2007, 5, 579–590.
  32. Tekoah, Y.; Tzaban, S.; Kizhner, T.; Hainrichson, M.; Gantman, A.; Golembo, M.; Aviezer, D.; Shaaltiel, Y. Glycosylation and Functionality of Recombinant β-Glucocerebrosidase from Various Production Systems. Biosci. Rep. 2013, 33, e00071.
  33. Khan, I.; Daniell, H. Oral Delivery of Therapeutic Proteins Bioencapsulated in Plant Cells: Preclinical and Clinical Advances. Curr. Opin. Colloid Interface Sci. 2021, 54, 101452.
  34. Fry, S.C. Plant Cell Wall Polymers. In Biofuels and Bioenergy; John Wiley & Sons, Ltd.: London, UK, 2017; pp. 59–87. ISBN 978-1-118-35055-3.
  35. Xiao, Y.; Kwon, K.-C.; Hoffman, B.E.; Kamesh, A.; Jones, N.T.; Herzog, R.W.; Daniell, H. Low Cost Delivery of Proteins Bioencapsulated in Plant Cells to Human Non-Immune or Immune Modulatory Cells. Biomaterials 2016, 80, 68–79.
  36. Sahoo, A.; Mandal, A.K.; Dwivedi, K.; Kumar, V. A Cross Talk between the Immunization and Edible Vaccine: Current Challenges and Future Prospects. Life Sci. 2020, 261, 118343.
  37. Iacobucci, I.; Hay Mele, B.; Cozzolino, F.; Monaco, V.; Cimmaruta, C.; Monti, M.; Andreotti, G.; Monticelli, M. Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy. Int. J. Mol. Sci. 2023, 24, 4548.
  38. Ioannou, Y.A.; Zeidner, K.M.; Gordon, R.E.; Desnick, R.J. Fabry Disease: Preclinical Studies Demonstrate the Effectiveness of Alpha-Galactosidase A Replacement in Enzyme-Deficient Mice. Am. J. Hum. Genet 2001, 68, 14–25.
  39. Umer, M.; Kalra, D.K. Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals 2023, 16, 320.
  40. Peng, L.-H.; Gu, T.-W.; Xu, Y.; Dad, H.A.; Liu, J.-X.; Lian, J.-Z.; Huang, L.-Q. Gene Delivery Strategies for Therapeutic Proteins Production in Plants: Emerging Opportunities and Challenges. Biotechnol. Adv. 2022, 54, 107845.
  41. Eidenberger, L.; Kogelmann, B.; Steinkellner, H. Plant-Based Biopharmaceutical Engineering. Nat. Rev. Bioeng. 2023, 1, 426–439.
  42. Sirko, A.; Vaněk, T.; Góra-Sochacka, A.; Redkiewicz, P. Recombinant Cytokines from Plants. Int. J. Mol. Sci. 2011, 12, 3536–3552.
  43. Rabindran, S.; Stevenson, N.; Roy, G.; Fedorkin, O.; Skarjinskaia, M.; Ensley, B.; Yusibov, V. Plant-Produced Human Growth Hormone Shows Biological Activity in a Rat Model. Biotechnol. Prog. 2009, 25, 530–534.
  44. Matsumoto, S.; Ikura, K.; Ueda, M.; Sasaki, R. Characterization of a Human Glycoprotein (Erythropoietin) Produced in Cultured Tobacco Cells. Plant Mol. Biol. 1995, 27, 1163–1172.
  45. Park, Y.; Cheong, H. Expression and Production of Recombinant Human Interleukin-2 in Potato Plants. Protein Expr. Purif. 2002, 25, 160–165.
  46. Patel, J.; Zhu, H.; Menassa, R.; Gyenis, L.; Richman, A.; Brandle, J. Elastin-like Polypeptide Fusions Enhance the Accumulation of Recombinant Proteins in Tobacco Leaves. Transgenic Res. 2007, 16, 239–249.
  47. Gutiérrez-Ortega, A.; Sandoval-Montes, C.; de Olivera-Flores, T.J.; Santos-Argumedo, L.; Gómez-Lim, M.Á. Expression of Functional Interleukin-12 from Mouse in Transgenic Tomato Plants. Transgenic Res. 2005, 14, 877–885.
  48. Wang, D.J.; Brandsma, M.; Yin, Z.; Wang, A.; Jevnikar, A.M.; Ma, S. A Novel Platform for Biologically Active Recombinant Human Interleukin-13 Production. Plant Biotechnol. J. 2008, 6, 504–515.
  49. Zhang, B.; Yang, Y.-H.; Lin, Y.-M.; Rao, Q.; Zheng, G.-G.; Wu, K.-F. Expression and Production of Bioactive Human Interleukin-18 in Transgenic Tobacco Plants. Biotechnol. Lett. 2003, 25, 1629–1635.
  50. Farran, I.; Río-Manterola, F.; Iñiguez, M.; Gárate, S.; Prieto, J.; Mingo-Castel, A.M. High-Density Seedling Expression System for the Production of Bioactive Human Cardiotrophin-1, a Potential Therapeutic Cytokine, in Transgenic Tobacco Chloroplasts. Plant Biotechnol. J. 2008, 6, 516–527.
  51. Shin, Y.-J.; Hong, S.-Y.; Kwon, T.-H.; Jang, Y.-S.; Yang, M.-S. High Level of Expression of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor in Transgenic Rice Cell Suspension Culture. Biotechnol. Bioeng. 2003, 82, 778–783.
  52. James, E.A.; Wang, C.; Wang, Z.; Reeves, R.; Shin, J.H.; Magnuson, N.S.; Lee, J.M. Production and Characterization of Biologically Active Human GM-CSF Secreted by Genetically Modified Plant Cells. Protein. Expr. Purif. 2000, 19, 131–138.
  53. Lee, J.-H.; Kim, N.-S.; Kwon, T.-H.; Jang, Y.-S.; Yang, M.-S. Increased Production of Human Granulocyte-Macrophage Colony Stimulating Factor (hGM-CSF) by the Addition of Stabilizing Polymer in Plant Suspension Cultures. J. Biotechnol. 2002, 96, 205–211.
  54. Kim, N.-S.; Kim, T.-G.; Jang, Y.-S.; Shin, Y.-J.; Kwon, T.-H.; Yang, M.-S. Amylase Gene Silencing by RNA Interference Improves Recombinant hGM-CSF Production in Rice Suspension Culture. Plant Mol. Biol. 2008, 68, 369–377.
  55. Ohya, K.; Itchoda, N.; Ohashi, K.; Onuma, M.; Sugimoto, C.; Matsumura, T. Expression of Biologically Active Human Tumor Necrosis Factor-Alpha in Transgenic Potato Plant. J. Interferon. Cytokine Res. 2002, 22, 371–378.
  56. Arlen, P.A.; Falconer, R.; Cherukumilli, S.; Cole, A.; Cole, A.M.; Oishi, K.K.; Daniell, H. Field Production and Functional Evaluation of Chloroplast-Derived Interferon-Alpha2b. Plant Biotechnol. J. 2007, 5, 511–525.
  57. Potula, H.H.S.K.; Kathuria, S.R.; Ghosh, A.K.; Maiti, T.K.; Dey, S. Transient Expression, Purification and Characterization of Bioactive Human Fibroblast Growth Factor 8b in Tobacco Plants. Transgenic Res. 2008, 17, 19–32.
  58. Daniell, H.; Ruiz, G.; Denes, B.; Sandberg, L.; Langridge, W. Optimization of Codon Composition and Regulatory Elements for Expression of Human Insulin like Growth Factor-1 in Transgenic Chloroplasts and Evaluation of Structural Identity and Function. BMC Biotechnol. 2009, 9, 33.
  59. Paddon, C.J.; Westfall, P.J.; Pitera, D.J.; Benjamin, K.; Fisher, K.; McPhee, D.; Leavell, M.D.; Tai, A.; Main, A.; Eng, D.; et al. High-Level Semi-Synthetic Production of the Potent Antimalarial Artemisinin. Nature 2013, 496, 528–532.
  60. Zhao, L.; Zhu, Y.; Jia, H.; Han, Y.; Zheng, X.; Wang, M.; Feng, W. From Plant to Yeast—Advances in Biosynthesis of Artemisinin. Molecules 2022, 27, 6888.
  61. Owen, C.; Patron, N.J.; Huang, A.; Osbourn, A. Harnessing Plant Metabolic Diversity. Curr. Opin. Chem. Biol. 2017, 40, 24–30.
  62. Gerasymenko, I.; Sheludko, Y.; Fräbel, S.; Staniek, A.; Warzecha, H. Chapter Sixteen—Combinatorial Biosynthesis of Small Molecules in Plants: Engineering Strategies and Tools. In Methods in Enzymology; Schmidt-Dannert, C., Quin, M.B., Eds.; Metabolons and Supramolecular Enzyme Assemblies; Academic Press: Cambridge, MA, USA, 2019; Volume 617, pp. 413–442.
  63. Reed, J.; Osbourn, A. Engineering Terpenoid Production through Transient Expression in Nicotiana Benthamiana. Plant Cell Rep. 2018, 37, 1431–1441.
  64. Stephenson, M.J.; Reed, J.; Brouwer, B.; Osbourn, A. Transient Expression in Nicotiana Benthamiana Leaves for Triterpene Production at a Preparative Scale. J. Vis. Exp. 2018, 138, e58169.
  65. Reed, J.; Orme, A.; El-Demerdash, A.; Owen, C.; Martin, L.B.B.; Misra, R.C.; Kikuchi, S.; Rejzek, M.; Martin, A.C.; Harkess, A.; et al. Elucidation of the Pathway for Biosynthesis of Saponin Adjuvants from the Soapbark Tree. Science 2023, 379, 1252–1264.
  66. Caputi, L.; Franke, J.; Farrow, S.C.; Chung, K.; Payne, R.M.E.; Nguyen, T.-D.; Dang, T.-T.T.; Soares Teto Carqueijeiro, I.; Koudounas, K.; Dugé de Bernonville, T.; et al. Missing Enzymes in the Biosynthesis of the Anticancer Drug Vinblastine in Madagascar Periwinkle. Science 2018, 360, 1235–1239.
  67. Grzech, D.; Hong, B.; Caputi, L.; Sonawane, P.D.; O’Connor, S.E. Engineering the Biosynthesis of Late-Stage Vinblastine Precursors Precondylocarpine Acetate, Catharanthine, Tabersonine in Nicotiana Benthamiana. ACS Synth. Biol. 2022, 12, 27–34.
  68. Chun-Ting Liu, J.; De La Pena, R.; Tocol, C.; Sattely, E.S. Reconstitution of Early Paclitaxel Biosynthetic Network. bioRxiv 2023, 9, 559859.
  69. Breitenbach Barroso Coelho, L.C.; Marcelino dos Santos Silva, P.; Felix de Oliveira, W.; de Moura, M.C.; Viana Pontual, E.; Soares Gomes, F.; Guedes Paiva, P.M.; Napoleão, T.H.; dos Santos Correia, M.T. Lectins as Antimicrobial Agents. J. Appl. Microbiol. 2018, 125, 1238–1252.
  70. Yau, T.; Dan, X.; Ng, C.C.W.; Ng, T.B. Lectins with Potential for Anti-Cancer Therapy. Molecules 2015, 20, 3791–3810.
  71. Mazalovska, M.; Kouokam, J.C. Plant-Derived Lectins as Potential Cancer Therapeutics and Diagnostic Tools. BioMed Res. Int. 2020, 2020, e1631394.
  72. Fu, L.; Zhou, C.; Yao, S.; Yu, J.; Liu, B.; Bao, J. Plant Lectins: Targeting Programmed Cell Death Pathways as Antitumor Agents. Int. J. Biochem. Cell Biol. 2011, 43, 1442–1449.
  73. Mazalovska, M.; Kouokam, J.C. Transiently Expressed Mistletoe Lectin II in Nicotiana Benthamiana Demonstrates Anticancer Activity In Vitro. Molecules 2020, 25, 2562.
  74. Rup, B.; Alon, S.; Amit-Cohen, B.-C.; Almon, E.B.; Chertkoff, R.; Tekoah, Y.; Rudd, P.M. Immunogenicity of Glycans on Biotherapeutic Drugs Produced in Plant Expression Systems—The Taliglucerase Alfa Story. PLoS ONE 2017, 12, e0186211.
  75. Wilson, I.B.; Harthill, J.E.; Mullin, N.P.; Ashford, D.A.; Altmann, F. Core Alpha1,3-Fucose Is a Key Part of the Epitope Recognized by Antibodies Reacting against Plant N-Linked Oligosaccharides and Is Present in a Wide Variety of Plant Extracts. Glycobiology 1998, 8, 651–661.
  76. Jin, C.; Bencúrová, M.; Borth, N.; Ferko, B.; Jensen-Jarolim, E.; Altmann, F.; Hantusch, B. Immunoglobulin G Specifically Binding Plant N-Glycans with High Affinity Could Be Generated in Rabbits but Not in Mice. Glycobiology 2006, 16, 349–357.
  77. Hemmer, W. Human IgE Antibodies Against Cross-Reactive Carbohydrate Determinants. In Anticarbohydrate Antibodies: From Molecular Basis to Clinical Application; Kosma, P., Müller-Loennies, S., Eds.; Springer: Vienna, Austria, 2012; pp. 181–202. ISBN 978-3-7091-0870-3.
  78. Aviezer, D.; Brill-Almon, E.; Shaaltiel, Y.; Hashmueli, S.; Bartfeld, D.; Mizrachi, S.; Liberman, Y.; Freeman, A.; Zimran, A.; Galun, E. A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation. PLoS ONE 2009, 4, e4792.
  79. Rybicki, E.P. Plant-Made Vaccines for Humans and Animals. Plant Biotechnol. J. 2010, 8, 620–637.
  80. Tacket, C.O.; Mason, H.S.; Losonsky, G.; Estes, M.K.; Levine, M.M.; Arntzen, C.J. Human Immune Responses to a Novel Norwalk Virus Vaccine Delivered in Transgenic Potatoes. J. Infect. Dis. 2000, 182, 302–305.
  81. Tacket, C.O.; Mason, H.S.; Losonsky, G.; Clements, J.D.; Levine, M.M.; Arntzen, C.J. Immunogenicity in Humans of a Recombinant Bacterial Antigen Delivered in a Transgenic Potato. Nat. Med. 1998, 4, 607–609.
  82. Tacket, C.O.; Pasetti, M.F.; Edelman, R.; Howard, J.A.; Streatfield, S. Immunogenicity of Recombinant LT-B Delivered Orally to Humans in Transgenic Corn. Vaccine 2004, 22, 4385–4389.
  83. Kapusta, J.; Modelska, A.; Pniewski, T.; Figlerowicz, M.; Jankowski, K.; Lisowa, O.; Plucienniczak, A.; Koprowski, H.; Legocki, A.B. Oral Immunization of Human with Transgenic Lettuce Expressing Hepatitis B Surface Antigen. Adv. Exp. Med. Biol. 2001, 495, 299–303.
  84. Wang, X.; Sherman, A.; Liao, G.; Leong, K.W.; Daniell, H.; Terhorst, C.; Herzog, R.W. Mechanism of Oral Tolerance Induction to Therapeutic Proteins. Adv. Drug Deliv. Rev. 2013, 65, 759–773.
  85. Fukuda, K.; Ishida, W.; Harada, Y.; Wakasa, Y.; Takagi, H.; Takaiwa, F.; Fukushima, A. Prevention of Allergic Conjunctivitis in Mice by a Rice-Based Edible Vaccine Containing Modified Japanese Cedar Pollen Allergens. Br. J. Ophthalmol. 2015, 99, 705–709.
  86. Sherman, A.; Su, J.; Lin, S.; Wang, X.; Herzog, R.W.; Daniell, H. Suppression of Inhibitor Formation against FVIII in a Murine Model of Hemophilia A by Oral Delivery of Antigens Bioencapsulated in Plant Cells. Blood 2014, 124, 1659–1668.
  87. Ma, S.W.; Zhao, D.L.; Yin, Z.Q.; Mukherjee, R.; Singh, B.; Qin, H.Y.; Stiller, C.R.; Jevnikar, A.M. Transgenic Plants Expressing Autoantigens Fed to Mice to Induce Oral Immune Tolerance. Nat. Med. 1997, 3, 793–796.
  88. Tsekoa, T.L.; Singh, A.A.; Buthelezi, S.G. Molecular Farming for Therapies and Vaccines in Africa. Curr. Opin. Biotechnol. 2020, 61, 89–95.
  89. Lee, V.C.-J.; Yao, J.; Zhang, W. The Health Impact Fund: Making the Case for Engagement with Pharmaceutical Laboratories in Brazil, Russia, India, and China. Glob. Health 2021, 17, 101.
  90. Buyel, J.F. Plants as Sources of Natural and Recombinant Anti-Cancer Agents. Biotechnol. Adv. 2018, 36, 506–520.
  91. Ma, J.K.-C.; Chikwamba, R.; Sparrow, P.; Fischer, R.; Mahoney, R.; Twyman, R.M. Plant-Derived Pharmaceuticals--the Road Forward. Trends Plant Sci. 2005, 10, 580–585.
  92. Shanmugaraj, B.; Malla, A.; Bulaon, C.J.I.; Phoolcharoen, W.; Phoolcharoen, N. Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer. Vaccines 2022, 10, 2064.
  93. Shanmugaraj, B.; Siriwattananon, K.; Malla, A.; Phoolcharoen, W. Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. Pathogens 2021, 10, 1051.
  94. Su, H.; van Eerde, A.; Rimstad, E.; Bock, R.; Branza-Nichita, N.; Yakovlev, I.A.; Clarke, J.L. Plant-Made Vaccines against Viral Diseases in Humans and Farm Animals. Front. Plant Sci. 2023, 14, 1170815.
  95. Hu, H.; Steinmetz, N.F. Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers 2021, 13, 2909.
  96. Gautam, A.; Beiss, V.; Wang, C.; Wang, L.; Steinmetz, N.F. Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy. Int. J. Mol. Sci. 2021, 22, 9733.
  97. Chariou, P.L.; Beiss, V.; Ma, Y.; Steinmetz, N.F. In Situ Vaccine Application of Inactivated CPMV Nanoparticles for Cancer Immunotherapy. Mater. Adv. 2021, 2, 1644–1656.
  98. Mao, C.; Beiss, V.; Ho, G.W.; Fields, J.; Steinmetz, N.F.; Fiering, S. In Situ Vaccination with Cowpea Mosaic Virus Elicits Systemic Antitumor Immunity and Potentiates Immune Checkpoint Blockade. J. Immunother. Cancer 2022, 10, e005834.
  99. Chung, Y.H.; Ortega-Rivera, O.A.; Volckaert, B.A.; Jung, E.; Zhao, Z.; Steinmetz, N.F. Viral Nanoparticle Vaccines against S100A9 Reduce Lung Tumor Seeding and Metastasis. Proc. Natl. Acad. Sci. USA 2023, 120, e2221859120.
  100. Chen, Q.; Davis, K.R. The Potential of Plants as a System for the Development and Production of Human Biologics. F1000Res 2016, 5, 912.
  101. Göritzer, K.; Grandits, M.; Grünwald-Gruber, C.; Figl, R.; Mercx, S.; Navarre, C.; Ma, J.K.-C.; Teh, A.Y.-H. Engineering the N-Glycosylation Pathway of Nicotiana Tabacum for Molecular Pharming Using CRISPR/Cas9. Front. Plant Sci. 2022, 13, 1003065.
  102. Strasser, R.; Altmann, F.; Mach, L.; Glössl, J.; Steinkellner, H. Generation of Arabidopsis Thaliana Plants with Complex N-Glycans Lacking Beta1,2-Linked Xylose and Core Alpha1,3-Linked Fucose. FEBS Lett. 2004, 561, 132–136.
  103. Castilho, A.; Strasser, R.; Stadlmann, J.; Grass, J.; Jez, J.; Gattinger, P.; Kunert, R.; Quendler, H.; Pabst, M.; Leonard, R.; et al. In Planta Protein Sialylation through Overexpression of the Respective Mammalian Pathway. J. Biol. Chem. 2010, 285, 15923–15930.
  104. Streatfield, S.J. Approaches to Achieve High-Level Heterologous Protein Production in Plants. Plant Biotechnol. J. 2007, 5, 2–15.
  105. Jutras, P.V.; D’Aoust, M.-A.; Couture, M.M.-J.; Vézina, L.-P.; Goulet, M.-C.; Michaud, D.; Sainsbury, F. Modulating Secretory Pathway pH by Proton Channel Co-Expression Can Increase Recombinant Protein Stability in Plants. Biotechnol. J. 2015, 10, 1478–1486.
  106. Jutras, P.V.; Dodds, I.; van der Hoorn, R.A. Proteases of Nicotiana Benthamiana: An Emerging Battle for Molecular Farming. Curr. Opin. Biotechnol. 2020, 61, 60–65.
  107. Vamvaka, E.; Twyman, R.M.; Murad, A.M.; Melnik, S.; Teh, A.Y.-H.; Arcalis, E.; Altmann, F.; Stoger, E.; Rech, E.; Ma, J.K.C.; et al. Rice Endosperm Produces an Underglycosylated and Potent Form of the HIV-Neutralizing Monoclonal Antibody 2G12. Plant Biotechnol. J. 2016, 14, 97–108.
  108. Scotti, N.; Alagna, F.; Ferraiolo, E.; Formisano, G.; Sannino, L.; Buonaguro, L.; De Stradis, A.; Vitale, A.; Monti, L.; Grillo, S.; et al. High-Level Expression of the HIV-1 Pr55gag Polyprotein in Transgenic Tobacco Chloroplasts. Planta 2009, 229, 1109–1122.
  109. Joensuu, J.J.; Verdonck, F.; Ehrström, A.; Peltola, M.; Siljander-Rasi, H.; Nuutila, A.M.; Oksman-Caldentey, K.-M.; Teeri, T.H.; Cox, E.; Goddeeris, B.M.; et al. F4 (K88) Fimbrial Adhesin FaeG Expressed in Alfalfa Reduces F4+ Enterotoxigenic Escherichia Coli Excretion in Weaned Piglets. Vaccine 2006, 24, 2387–2394.
  110. Lamphear, B.J.; Jilka, J.M.; Kesl, L.; Welter, M.; Howard, J.A.; Streatfield, S.J. A Corn-Based Delivery System for Animal Vaccines: An Oral Transmissible Gastroenteritis Virus Vaccine Boosts Lactogenic Immunity in Swine. Vaccine 2004, 22, 2420–2424.
  111. Thanavala, Y.; Mahoney, M.; Pal, S.; Scott, A.; Richter, L.; Natarajan, N.; Goodwin, P.; Arntzen, C.J.; Mason, H.S. Immunogenicity in Humans of an Edible Vaccine for Hepatitis B. PNAS 2005, 102, 3378–3382.
  112. Xu, J.; Zhang, N. On the Way to Commercializing Plant Cell Culture Platform for Biopharmaceuticals: Present Status and Prospect. Pharm. Bioprocess. 2014, 2, 499–518.
  113. Vermij, P.; Waltz, E. USDA Approves the First Plant-Based Vaccine. Nat. Biotechnol. 2006, 24, 234.
  114. Mor, T.S. Molecular Pharming’s Foot in the FDA’s Door: Protalix’s Trailblazing Story. Biotechnol. Lett. 2015, 37, 2147–2150.
  115. Gasdaska, J.R.; Spencer, D.; Dickey, L. Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna. Bioprocess. J. 2003, 2, 49–56.
  116. Buntru, M.; Vogel, S.; Spiegel, H.; Schillberg, S. Tobacco BY-2 Cell-Free Lysate: An Alternative and Highly-Productive Plant-Based in Vitro Translation System. BMC Biotechnol. 2014, 14, 37.
  117. Bally, J.; Jung, H.; Mortimer, C.; Naim, F.; Philips, J.G.; Hellens, R.; Bombarely, A.; Goodin, M.M.; Waterhouse, P.M. The Rise and Rise of Nicotiana Benthamiana: A Plant for All Reasons. Annu. Rev. Phytopathol. 2018, 56, 405–426.
  118. Molina-Hidalgo, F.J.; Vazquez-Vilar, M.; D’Andrea, L.; Demurtas, O.C.; Fraser, P.; Giuliano, G.; Bock, R.; Orzáez, D.; Goossens, A. Engineering Metabolism in Nicotiana Species: A Promising Future. Trends. Biotechnol. 2021, 39, 901–913.
  119. Schiermeyer, A. Optimizing Product Quality in Molecular Farming. Curr. Opin. Biotechnol. 2020, 61, 15–20.
  120. Mardanova, E.S.; Blokhina, E.A.; Tsybalova, L.M.; Peyret, H.; Lomonossoff, G.P.; Ravin, N.V. Efficient Transient Expression of Recombinant Proteins in Plants by the Novel pEff Vector Based on the Genome of Potato Virus X. Front. Plant Sci. 2017, 8, 247.
  121. Klimyuk, V.; Pogue, G.; Herz, S.; Butler, J.; Haydon, H. Production of Recombinant Antigens and Antibodies in Nicotiana Benthamiana Using ‘Magnifection’ Technology: GMP-Compliant Facilities for Small- and Large-Scale Manufacturing. In Plant Viral Vectors; Palmer, K., Gleba, Y., Eds.; Current Topics in Microbiology and Immunology; Springer: Berlin, Heidelberg, 2014; pp. 127–154. ISBN 978-3-642-40829-8.
  122. Goodin, M.M.; Zaitlin, D.; Naidu, R.A.; Lommel, S.A. Nicotiana Benthamiana: Its History and Future as a Model for Plant-Pathogen Interactions. Mol. Plant Microbe Interact. 2008, 21, 1015–1026.
  123. Palmer, K.; Gleba, Y. Plant Viral Vectors; Springer: Berlin/Heidelberg, Germany, 2013; Volume 375, ISBN 3-642-40829-X.
  124. Takamatsu, N.; Ishikawa, M.; Meshi, T.; Okada, Y. Expression of Bacterial Chloramphenicol Acetyltransferase Gene in Tobacco Plants Mediated by TMV-RNA. EMBO J. 1987, 6, 307–311.
  125. Howell, S.H.; Walker, L.L.; Dudley, R.K. Cloned Cauliflower Mosaic Virus DNA Infects Turnips (Brassica Rapa). Science 1980, 208, 1265–1267.
  126. Lico, C.; Chen, Q.; Santi, L. Viral Vectors for Production of Recombinant Proteins in Plants. J. Cell Physiol. 2008, 216, 366–377.
  127. Grimsley, N.; Hohn, B.; Hohn, T.; Walden, R. “Agroinfection,” an Alternative Route for Viral Infection of Plants by Using the Ti Plasmid. Proc. Natl. Acad. Sci. USA 1986, 83, 3282–3286.
  128. Giritch, A.; Marillonnet, S.; Engler, C.; van Eldik, G.; Botterman, J.; Klimyuk, V.; Gleba, Y. Rapid High-Yield Expression of Full-Size IgG Antibodies in Plants Coinfected with Noncompeting Viral Vectors. Proc. Natl. Acad. Sci. USA 2006, 103, 14701–14706.
  129. Saxena, P.; Thuenemann, E.C.; Sainsbury, F.; Lomonossoff, G.P. Virus-Derived Vectors for the Expression of Multiple Proteins in Plants. In Recombinant Proteins from Plants: Methods and Protocols; MacDonald, J., Kolotilin, I., Menassa, R., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2016; pp. 39–54. ISBN 978-1-4939-3289-4.
  130. Peyret, H.; Lomonossoff, G.P. When Plant Virology Met Agrobacterium: The Rise of the Deconstructed Clones. Plant Biotechnol. J. 2015, 13, 1121–1135.
  131. Marillonnet, S.; Giritch, A.; Gils, M.; Kandzia, R.; Klimyuk, V.; Gleba, Y. In Planta Engineering of Viral RNA Replicons: Efficient Assembly by Recombination of DNA Modules Delivered by Agrobacterium. Proc. Natl. Acad. Sci. USA 2004, 101, 6852–6857.
  132. Pinneh, E.C.; van Dolleweerd, C.J.; Göritzer, K.; Drake, P.M.W.; Ma, J.K.-C.; Teh, A.Y.-H. Multiple Gene Expression in Plants Using MIDAS-P, a Versatile Type II Restriction-Based Modular Expression Vector. Biotechnol. Bioeng. 2022, 119, 1660–1672.
  133. Castilho, A.; Neumann, L.; Daskalova, S.; Mason, H.S.; Steinkellner, H.; Altmann, F.; Strasser, R. Engineering of Sialylated Mucin-Type O-Glycosylation in Plants. J. Biol. Chem. 2012, 287, 36518–36526.
  134. Castilho, A.; Gattinger, P.; Grass, J.; Jez, J.; Pabst, M.; Altmann, F.; Gorfer, M.; Strasser, R.; Steinkellner, H. N-Glycosylation Engineering of Plants for the Biosynthesis of Glycoproteins with Bisected and Branched Complex N-Glycans. Glycobiology 2011, 21, 813–823.
  135. Li, J.; Stoddard, T.J.; Demorest, Z.L.; Lavoie, P.-O.; Luo, S.; Clasen, B.M.; Cedrone, F.; Ray, E.E.; Coffman, A.P.; Daulhac, A.; et al. Multiplexed, Targeted Gene Editing in Nicotiana Benthamiana for Glyco-Engineering and Monoclonal Antibody Production. Plant Biotechnol. J. 2016, 14, 533–542.
  136. Jansing, J.; Sack, M.; Augustine, S.M.; Fischer, R.; Bortesi, L. CRISPR/Cas9-Mediated Knockout of Six Glycosyltransferase Genes in Nicotiana Benthamiana for the Production of Recombinant Proteins Lacking β-1,2-Xylose and Core α-1,3-Fucose. Plant Biotechnol. J. 2019, 17, 350–361.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Biotechnology & Applied Microbiology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Gergana Zahmanova
,
Alaa A. A. Aljabali
,
Katerina Takova
,
George Minkov
,
Murtaza M. Tambuwala
,
Ivan Minkov
,
George P. Lomonossoff
View Times: 172
Revisions: 2 times (View History)
Update Date: 20 Dec 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback